An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia



Status:Recruiting
Healthy:No
Age Range:18 - 80
Updated:3/27/2019
Start Date:October 3, 2018
End Date:August 2020
Contact:Sara H Barbat
Email:sbarbat@amplyx.com
Phone:858-876-6546

Use our guide to learn which trials are right for you!

An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Non Neutropenic Patients With Candidemia, With or Without Invasive Candidiasis, Inclusive of Patients With Suspected Resistance to Standard of Care Antifungal Treatment

This is a multicenter, open-label, non-comparative, single-arm study to evaluate the efficacy
and safety of APX001 for the first-line treatment for candidemia including suspected or
confirmed antifungal-resistant candidemia in non-neutropenic patients 18 to 80 years of age
(inclusive).

Suspicion of antifungal-resistant candidemia is sufficient (documented resistance is not
required for enrollment). The Study Drug Treatment Period of APX001 will be a maximum of 14
days. After completion of 14 days study drug therapy, if further antifungal treatment is
indicated to complete treatment of candidemia in accordance with standard practice
guidelines, fluconazole (unless susceptibility results warrant alternative antifungal
therapy) may commence for up to a further 7 days. There will be a Follow up Period of 4 weeks
(+4 days) after EOT. The total duration of participation in the study is up to approximately
7.5 weeks.

This study will be conducted at approximately 20 sites in the United States and globally.


Key Inclusion Criteria:

- Provision of written consent

- Ages 18-80 inclusive, male or female

- New diagnosis of candidemia

- Able to have pre-existing intravascular catheters removed and replaced (as necessary)

Key Exclusion Criteria:

- neutropenia

- deep-seated Candida-related infections

- hepatosplenic candidiasis

- received more than 2 days of prior systemic antifungal treatment for current
candidemia episode

- severe hepatic impairment
We found this trial at
8
sites
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Birmingham, Alabama 35294
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Brussels,
Click here to add this to my saved trials
Davis, California 95616
?
mi
from
Davis, CA
Click here to add this to my saved trials
Durham, North Carolina 27710
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials